Skip to main content

Prevention and Management of Infection in Children with Sickle Cell Anaemia

Paediatric Drugs volume 3, pages 793–801 (2001)Cite this article

Abstract

Sickle cell anaemia (SCA) predisposes a child to infections for various reasons, including increased bone marrow turnover, poor perfusion and functional asplenia leading to decreased opsonisation of polysaccharide encapsulated organisms. Bacteria and viruses that most frequently cause serious infections in children with sickle cell disease are Streptococcus pneumoniae, Haemophilus influenzae type b, Salmonella spp., Escherichia coli, Staphylococcus aureus, Mycoplasma pneumoniae, Chlamydia pneumoniae, parvovirus B19 and hepatitis A, B and C viruses.

Penicillin prophylaxis has decreased the incidence of infection-related morbidity and mortality significantly in children with SCA. Children <3 years of age are administered oral penicillin 125mg twice daily, and the dose is increased to 250mg twice daily for the >3 to 5 year age group. Adherence to the penicillin prophylactic regimen is recommended for children with SCA who are >5 years of age. For children with SCA who have recurrent invasive pneumococcal infections, an effort is made to keep the child on penicillin prophylaxis indefinitely.

The administration of various childhood vaccines has also made an appreciable impact on the overall morbidity and mortality associated with infection in children with SCA. The administration of the heptavalent conjugate pneumococcal vaccine (PCV7) has provided control of invasive pneumococcal infections, and the prophylactic use of the H. influenzae type b conjugate vaccine has reduced the incidence of septicaemia and meningitis caused by this organism. Other vaccines used prophylactically in children with SCA include hepatitis A and B, and vaccines against influenza and varicella viruses.

The immediate administration of intravenous antibacterials, after appropriate blood and urine cultures, is of great importance in the treatment of the febrile child with SCA. Ceftriaxone and cefotaxime have been recommended for the treatment of septic episodes in SCA associated with S. pneumoniae, Haemophilus and Salmonella spp. Infection with Yersinia enterocolitica may be treated with cefotaxime or an aminoglycoside. The prevalence of Helicobacter pylori infection in SCA is unknown. Effective therapies include metronidazole, tetracycline or amoxicillin. Parvovirus infections require supportive care and specific antiviral therapy is not indicated.

The judicious use of antimicrobials is encouraged in view of the worldwide emergence of multidrug-resistant strains. The long term sequelae associated with infections in children with SCA can be decreased with the implementation of immunisation programmes and effective and prompt treatment with appropriate antibacterials.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

49,54 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Table I
Fig. 1

References

  1. Barrett-Conner E. Bacterial infection and sickle cell anemia: an analysis of 250 infections in 166 patients and a review of the literature. Medicine 1971; 50: 97–112

    Google Scholar 

  2. Gill FM, Sleeper LA, Weiner SJ, et al. and the Cooperative Study of Sickle Cell Disease. Clinical events in the first decade in a cohort of infants with sickle cell disease. Blood 1995; 86: 776–83

    PubMed  CAS  Google Scholar 

  3. Zarkowsky HS, Gallagher D, Gill FM, et al. and the Cooperative Study of Sickle Cell Disease. Bacteremia in sickle hemoglobinopathies. J Pediatr 1986; 109: 579–85

    PubMed  Article  CAS  Google Scholar 

  4. Murphy TV, White KE, Pastor P, et al. Declining incidence of haemophilus influenzae type B disease since introduction of vaccination. JAMA 1993; 269(2): 246–8

    PubMed  Article  CAS  Google Scholar 

  5. Wong WY, Powars DR, Chan L, et al. Polysaccharide encapsulated bacterial infection in sickle cell anemia: a thirty year epidemiologic experience. Am J Hematol 1992; 39: 176–82

    PubMed  Article  CAS  Google Scholar 

  6. Overturf GD, Powars D, Baraff LJ. Bacterial meningitis and septicemia in sickle cell disease. Am J Dis Child 1977; 131: 784–7

    PubMed  CAS  Google Scholar 

  7. Gray BM, Dillon Jr HC. Clinical and epidemiologic studies of pneumococcal infection in children. Pediatr Infect Dis J 1986; 5: 201–7

    Article  CAS  Google Scholar 

  8. Orange M, Gray BM. Pneumococcal serotypes causing disease in Alabama. Pediatr Infect Dis J 1993; 12: 244–6

    PubMed  Article  CAS  Google Scholar 

  9. Gaston MH, Verter JI, Woods G, et al. for the Prophylactic Penicillin Study Group. Prophylaxis with oral penicillin in children with sickle cell anemia. N Engl J Med 1986; 314: 1593–9

    PubMed  Article  CAS  Google Scholar 

  10. Buchanan GR, Smith SJ. Pneumococcal septicemia despite pneumococcal vaccine and prescription of penicillin prophylaxis in children with sickle cell anemia. Am J Dis Child 1986; 140: 428–32

    PubMed  CAS  Google Scholar 

  11. Chesney PJ, Davis Y, English BK, et al. Occurrence of streptococcus pneumoniae meningitis during vancomycin and cefotaxime therapy of septicemia in a patient with sickle cell disease. Pediatr Infect Dis J 1995; 14: 1013–5

    PubMed  Article  CAS  Google Scholar 

  12. Kaplan SL, Mason EO, Barson WJ, et al. Three-year multicenter surveillance of systemic pneumococcal infections in children. Pediatrics 1998; 102: 538–45

    PubMed  Article  CAS  Google Scholar 

  13. Buchanan GR, Siegel JD, Smith SJ, et al. Oral penicilin prophylaxis in children with impaired splenic function: a study of compliance. Pediatrics 1982; 70: 926–30

    PubMed  CAS  Google Scholar 

  14. Berkovitch M, Papadouris D, Shaw D, et al. Trying to improve compliance with prophylactic penicillin therapy in children with sickle cell disease. Br J Clin Pharmacol 1998; 45: 605–7

    PubMed  Article  CAS  Google Scholar 

  15. Teach SJ, Lillis KA, Grossi M. Compliance with penicillin prophylaxis in patients with sickle cell disease. Arch Pediatr Adolesc Med 1998; 152: 274–8

    PubMed  CAS  Google Scholar 

  16. Falletta JM, Woods GM, Verter JI, et al. for the Prophylactic Penicilin Study II. Discontinuing penicillin prophylaxis in children with sickle cell anemia. J Pediatr 1995; 127: 685–90

    PubMed  Article  CAS  Google Scholar 

  17. Hongeng S, Wilimas JA, Harris S, et al. Recurrent streptococcus pneumoniae sepsis in children with sickle cell disease. J Pediatr 1997; 130: 814–6

    PubMed  Article  CAS  Google Scholar 

  18. Shinefield AM, Black S, Ray P, et al. Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers. Pediatr Infect Dis J 1999; 18: 757–63

    PubMed  Article  CAS  Google Scholar 

  19. Vernacchio L, Neufield EJ, MacDonald K, et al. Combined schedule of 7-valent pneumococcal conjugate vaccine followed by 23-valnet pneumococcal vaccine in children and young adults with sickle cell disease. J Pediatr 1998; 133: 275–8

    PubMed  Article  CAS  Google Scholar 

  20. O’Brien KL, Swift AJ, Winkelstein JA, et al. for the Pneumococcal Conjugate Vaccine Study Group. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 among infants with sickle cell anemia. Pediatrics 2000; 106: 965–72

    PubMed  Article  Google Scholar 

  21. American Academy of Pediatrics, Committee on Infectious Diseases. Policy statement: recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. Pediatrics 2000; 106: 362–6

    Article  Google Scholar 

  22. Rennels MB, Edwards KM, Keyserling HL, et al. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. Pediatrics 1998; 102: 604–11

    Article  Google Scholar 

  23. Wong WY, Powars DR, Overturf GD. Infections in children with sickle cell anemia. Infect Med 1995; 12: 331–8

    Google Scholar 

  24. Rogers ZR, Morrison RA, Vedro DA, et al. Outpatient management of febrile illness in infants and young children with sickle cell anemia. J Pediatr 1990; 117: 736–9

    PubMed  Article  CAS  Google Scholar 

  25. Wilimas JA, Flynn PM, Harris S, et al. A randomized study of outpatient treatment with ceftriaxone for selected febrile children with sickle cell disease. N Engl J Med 1993; 329: 472–6

    PubMed  Article  CAS  Google Scholar 

  26. Viner Y, Hashkes PJ, Yakubova R, et al. Severe hemolysis induced by ceftriaxone in a child with sickle cell anemia. Pediatr Infect Dis J 2000; 19: 83–5

    PubMed  Article  CAS  Google Scholar 

  27. Marshall WF, Blair JE. The cephalosporins. Mayo Clin Proc 1999; 74(2): 187–95

    PubMed  Article  CAS  Google Scholar 

  28. Magnus SA, Hambleton IR, Moosdeen F, et al. Recurrent infections in homozygous sickle cell disease. Arch Dis Child 1999; 80(6): 537–41

    PubMed  Article  CAS  Google Scholar 

  29. Workman MR, Philpott-Howard J, Bragman S, et al. Emergence of ciprofloxacin resistance during treatment of salmonella osteomyelitis in three patients with sickle cell disease. J Infect 1996; 32: 27–32

    PubMed  Article  CAS  Google Scholar 

  30. Blei F, Puder DR. Yersinia enterocolitica bacteremia in a chronically transfused patient with sickle cell anemia: case report and review of the literature. Am J Pediatr Hematol Oncol 1993; 15(4): 430–4

    PubMed  CAS  Google Scholar 

  31. Stoddard JJ, Wechsler DS, Nataro JP, et al. Yersinia enterocolitica infection in a patient with sickle cell disease after exposure to chitterlings. Am J Pediatr Hematol Oncol 1995; 16(2): 153–5

    Google Scholar 

  32. Chong SKF, Lou Q, Asnicar MA, et al. Helicobacter pylori infection in recurrent abdominal pain in childhood: comparison of diagnostic tests and therapy. Pediatrics 1995; 96: 211–5

    PubMed  CAS  Google Scholar 

  33. American Academy of Pediatrics, Committee on Infectious Diseases. Therapy for children with invasive pneumococcal infections. Pediatrics 1997; 99: 289–99

    Article  Google Scholar 

  34. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing: 18th informational supplement. Villanova (PA): NCCLS, 1998: Publication no. NCCLS M100-S8

    Google Scholar 

  35. Wang WC, Wong WY, Rogers ZR, et al. Antibiotic-resistant pneumococcal infection in children with sickle cell disease in the United States. J Pediatr Hematol Oncol 1996; 18: 140–4

    PubMed  Article  CAS  Google Scholar 

Download references

Author information

Affiliations

  1. Division of Hematology/Oncology, Childrens Hospital Los Angeles, Mailstop #54, 4650 Sunset Boulevard, Los Angeles, California, 90027, USA

    Wing-Yen Wong

Authors
  1. Wing-Yen Wong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wing-Yen Wong.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Wong, WY. Prevention and Management of Infection in Children with Sickle Cell Anaemia. Pediatr-Drugs 3, 793–801 (2001). https://doi.org/10.2165/00128072-200103110-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128072-200103110-00002

Keywords

  • Sickle Cell Anaemia
  • Methicillin Resistant Staphylococcus Aureus
  • Pneumococcal Infection
  • Yersinia Enterocolitica
  • Vancomycin Resistant Enterococcus